72388-13-7 Usage
General Description
1-(2-Hydroxyethyl)-4-methanesulfonylpiperazine is a chemical compound with the molecular formula C7H16N2O3S. It is a piperazine derivative that is commonly used in the pharmaceutical industry as an intermediate in the synthesis of various drugs. 1-(2-HYDROXYETHYL)-4-METHANESULFONYLPIPERAZINE is known for its ability to act as a bioisosteric replacement for various functional groups, allowing for the modification of drug molecules. 1-(2-Hydroxyethyl)-4-methanesulfonylpiperazine also has potential as a chelating agent and has been studied for its role in metal ion binding. Additionally, it has been investigated for its potential use in the development of new materials and coatings.
Check Digit Verification of cas no
The CAS Registry Mumber 72388-13-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,2,3,8 and 8 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 72388-13:
(7*7)+(6*2)+(5*3)+(4*8)+(3*8)+(2*1)+(1*3)=137
137 % 10 = 7
So 72388-13-7 is a valid CAS Registry Number.
InChI:InChI=1/C7H16N2O3S/c1-13(11,12)9-4-2-8(3-5-9)6-7-10/h10H,2-7H2,1H3
72388-13-7Relevant articles and documents
ADENOSINE RECEPTOR BINDING COMPOUNDS
-
, (2020/02/06)
The present invention relates to pharmaceutical compounds and compositions of Formula (I) and methods of treatment using the compounds and compositions, especially for the treatment and/or prevention of a proliferation disorder, such as cancer. Compounds of Formula (I) as further described herein are shown modulators of the adenosine A2A receptor and exhibit antiproliferative activity. Accordingly, these compounds are useful to treat proliferative disorders such as cancer, and other adenosine receptor-related conditions including an inflammatory disease, renal disease, diabetes, vascular disease, lung disease, or an autoimmune disease.
Piperazine- and piperidine-derivatives as melanocortin receptor agonists
-
Page/Page column 42, (2010/02/06)
The present invention relates to melanocortin receptor agonists of formula I, which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction.
